The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Sequential first-line treatment for metastatic colorectal cancer with capecitabine, irinotecan, and bevacizumab: Capecitabine plus bevacizumab (Cape-Bev) versus capecitabine, irinotecan plus bevacizumab (CAPIRI-Bev): The AIO KRK 0110/ML22011 randomized, phase III trial.
Clemens Albrecht Giessen
Other Remuneration - Roche
Dominik Paul Modest
Honoraria - Amgen
Other Remuneration - Merck Serono
Sebastian Stintzing
Honoraria - Merck Serono
Other Remuneration - Merck Serono; Roche
Ludwig Fischer von Weikersthal
No relevant relationships to disclose
Ursula Vehling-Kaiser
No relevant relationships to disclose
Ernst Spaeth-Schwalbe
No relevant relationships to disclose
Jens Freiberg-Richter
No relevant relationships to disclose
Julia Mayerle
No relevant relationships to disclose
Markus Bangerter
No relevant relationships to disclose
Claudio Denzlinger
No relevant relationships to disclose
Markus Sieber
No relevant relationships to disclose
Christian Teschendorf
No relevant relationships to disclose
Bettina Peuser
No relevant relationships to disclose
Volker Heinemann
Consultant or Advisory Role - Roche
Honoraria - Merck Serono; Roche
Research Funding - Roche
Other Remuneration - Merck Serono; Roche